Amniotics is featured on TV4 for their novel source of MSCs to treat COVID-19

Amniotics is featured on TV4 for their novel source of MSCs to treat COVID-19

Amniotics has developed a unique pipeline of cell therapeutics combining the desirable properties of neonatal source and tissue specificity.

As shown in the feature on TV4 (https://www.tv4play.se/program/nyheterna/12582143?utm_source=permalink&utm_medium=sharing&utm_campaign=tv4play_sharing) Amniotics cells originate from full term amniotic fluid, collected at planned cesarean sections and processed with technology which ensures that properties ideal for regenerative and immunomodulatory medicine are maintained and enhanced. Amniotics has developed a proprietary method and a device for the extraction and use of the amniotic fluid material. The material is collected and processed according to GMP (good manufacturing practice) protocols in Amniotics fully owned facilities.

The worldwide outbreak of the novel Coronavirus, SARS-CoV-2, which can lead to a previously unidentified viral pneumonia, which has now been named COVID-19 has the world scrambling for a cure. Despite all efforts, mortality of COVID-19 remains high. Moreover, the treatment duration in the intensive care unit (ICU) is long, up to several weeks, thereby blocking each bed and ventilator from treating a new patient. Thus, new therapeutic options are in dire need.

In the TV feature, a study by Leng et al. (http://www.aginganddisease.org/EN/10.14336/AD.2020.0228) using mesenchymal stem cells on a small group of COVID-19 patients is referred to. Amniotics would like to clarify that all 7 patients treated with MSCs in this study recovered, whereas the three patients in the control group did not. The published data, indicates that the MSCs downregulate the so-called cytokine storm, thereby helping the patients to recover.

Amniotics product, PulmiCell, is tailored to a specific organ of choice, the lung, for treatment of COVID-19. Amniotics technology combines the potency, proliferative capacity, and differentiation capability of neonatal cells with tissue-relevance, making it possible to treat corresponding tissues. This makes Amniotics pipeline ideally suited for therapies in which there is a need for organ-specific repair, with an elevated chance of success in treatment.

Amniotics